Clinical Trial Update: Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a DPP-4 inhibitor for hyperglycemia control in COVID-19 patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperglycemia

Drugs mentioned

• Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor)

Snippet

Sponsor: Hospital Regional de Alta Especialidad del Bajio | Conditions: Hyperglycemia, Covid19 | Phase 3 | Status: COMPLETED